The latest issue of Insights on Metastatic Breast Cancer helps you understand the U.S. Food and Drug Administration's authority over approval of medicines for breast cancer treatment. On the eve of FDA's decision about the fate of bevacizumab (Avastin) for stage IV breast cancer, this article explores the controversy over the value of progression-free survival, surrogate endpoints and clinical benefits. Find out how the FDA ruling could impact access to bevacizumab. Also in this issue: Lisa Marsella shares her perspective on why metastatic breast cancer is like a carnival, and in the poem "Hair," Darlene Barela Cooke explores her reactions to losing what she once considered her "best feature."
Insights on Metastatic Breast Cancer, Winter 2010/2011